90024 Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 

to licensing should be directed to 

Andrew Burke, Ph.D., Senior 

Technology Transfer Manager, NCI, 

Technology Transfer Center, Email: 

burkear@mail.nih.gov or Phone: 240– 

276–5484. 

SUPPLEMENTARY INFORMATION: Success in 

immunotherapy is often attributable to 

the reactivity of patient T-cells to 

specific mutated peptide(s) found in the 

patient’s tumor known as neoepitopes. 

In the development of patient-specific 

immunotherapies, there is no consistent 

standard for prioritizing such 

neoepitopes. Current models arrive at a 

ranked list of potential candidates by 

removing epitopes based on predetermined criteria which might lead to 

the elimination of known reactive 

neoepitopes. Identification, 

prioritization and targeting of patient 

neoepitopes are crucial for developing 

effective, personalized treatments. 

Ranking or prioritizing neoepitopes is 

especially important when trying to 

construct a cancer vaccine that will 

elicit a therapeutically beneficial 

immune response. Accordingly, 

scientists at the NCI created a novel 

approach to identify and prioritize 

patient neoantigens. This model uses a 

training dataset of known neoantigens 

from patient screening and determines 

features of importance to epitope 

recognition using both reactive and nonreactive epitopes. The machine learning 

algorithm scores epitopes for their 

likelihood of reactivity and provides a 

stable, reproducible method to prioritize 

epitopes that can be used anywhere. 

This Notice is in accordance with 35 

U.S.C. 209 and 37 CFR part 404. 

NIH Reference Number: E–022–2024– 

0. 

Potential Commercial Applications 

• Oncology. 

• Prioritization of neoantigens for the 

development of effective personalized 

therapies: 

Æ Cancer vaccines. 

Æ TIL and T-cell receptor therapies. 

• Add-on to current color fundus 

imaging modalities. 

Competitive Advantages 

• Model is trained using a dataset of 

verified neoantigens from patient tumor 

data. 

• Model is unbiased because it does 

not use prior assumptions about what 

features a neoepitope should have. 

• Uses two models (MMP and NMER 

model) as a more reproducible approach 

than a single model. 

• Particularly useful for prioritizing 

epitopes for patients with large numbers 

of mutations. 

Publication: A machine learning 

model for ranking candidate HLA class 

I neoantigens based on known 

neoepitopes from multiple human 

tumor types. (PMID: 34927080). 

Product Type: Research Tool. 

Development Stage: Prototype. 

Therapeutic Area(s): Cancer. 

Dated: November 8, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–26464 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board (NCAB) and NCI Board 

of Scientific Advisors (BSA). 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public as indicated below. 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/. 

A portion of the National Cancer 

Advisory Board meeting will be closed 

to the public in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended. 

The intramural programs and projects 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the 

intramural programs and projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Date: December 2, 2024. 

Open: 6:00 p.m. to 9:00 p.m. 

Agenda: National Cancer Advisory Board 

Subcommittee Meetings. 

Place: Gaithersburg Marriott 

Washingtonian Center, Room—TBD, 9751 

Washington Boulevard, Gaithersburg, MD 

20878 (In Person Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Name of Committee: National Cancer 

Advisory Board. 

Date: December 3, 2024. 

Closed: 8:00 a.m. to 8:45 a.m. 

Agenda: Review of intramural program site 

visit outcomes and the discussion of 

confidential personnel issues. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Room 

TE406 & 408, Rockville, MD 20850 (In Person 

and Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room. 7W444, 

Bethesda, MD 20892 240–276–6340, grayp@

mail.nih.gov. 

Name of Committee: National Cancer 

Advisory Board and NCI Board of Scientific 

Advisors. 

Date: December 3, 2024. 

Open: 9:00 a.m. to 4:00 p.m. 

Agenda: Joint meeting of the National 

Cancer Advisory Board and NCI Board of 

Scientific Advisors, NCI Director’s report and 

presentations, NCI Board of Scientific 

Advisors Concepts Review. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Room 

TE406 & 408, Rockville, MD 20850 (In Person 

and Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room 7W444, 

Bethesda, MD 20892 240–276–6340 grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NCI-Shady Grove campus. All 

visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: NCAB: http:// 

deainfo.nci.nih.gov/advisory/ncab/ 

ncab.htm,BSA: http://deainfo.nci.nih.gov/ 

advisory/bsa/bsa.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices 90025 

Dated: November 7, 2024. 

David W. Freeman, 

Supervisory Program Analyst Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26430 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: Member 

Conflict: Molecular Genetics and Evolution. 

Date: December 9, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Linda Wagner Jurata, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health. 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–8032, linda.jurata@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: Biomedical 

Imaging and Cardiovascular and Surgical 

Devices. 

Date: December 10, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Krystyna H. Szymczyk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–4198, szymczykk@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel PAR Panel: 

Countermeasures Against Chemical Threats 

Exploratory/Developmental and Full 

Projects. 

Date: December 10, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jonathan K. Ivins, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2190, 

MSC 7850, Bethesda, MD 20892 (301) 594– 

1245, ivinsj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: Member 

Conflict: Topics in HIV Comorbidities, 

Coinfections and Associated Cancers. 

Date: December 10, 2024. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Raul Rojas, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6185, 

Bethesda, MD 20892, (301) 451–6319, rojasr@

mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: PAR–24– 

174: Fogarty Global Infectious Disease 

Research Training Program. 

Date: December 10, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dayadevi Jirage, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4422, 

Bethesda, MD 20892, (301) 867–5309, 

jiragedb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: Member 

Conflict: Skin and Connective Tissue 

Sciences. 

Date: December 10, 2024. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Yi-Hsin Liu, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, Bethesda, MD 20892, (301) 435–1781, 

liuyh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel: Member 

Conflict: Adaptive and Innate Immunity 

Special Emphasis Panel. 

Date: December 10, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Susan Daum, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

Bethesda, MD 20892, 301–827–7233, 

susan.boyle-vavra@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 8, 2024. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2024–26496 Filed 11–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Nursing Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Registration is not required to attend 

this meeting. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following link: https://

videocast.nih.gov/. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The intramural programs 

and projects as well as the grant 

applications and/or contract proposals 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: The National 

Advisory Council for Nursing Research 

(NACNR). 

Date: January 28, 2025. 

Open: 9:00 a.m. to 3:00 p.m. 

Agenda: Call to Order and Opening 

Remarks, NINR Director’s Report, Discussion 

of NINR Programs, Council Open Discussion. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Room 6C, 

Bethesda, MD 20892 (Hybrid Meeting). 


ddrumheller on DSK120RN23PROD with NOTICES1